Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

158.96USD
23 Aug 2019
Change (% chg)

$-1.97 (-1.22%)
Prev Close
$160.93
Open
$160.60
Day's High
$161.12
Day's Low
$158.31
Volume
756,038
Avg. Vol
784,450
52-wk High
$197.00
52-wk Low
$114.27

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

Financials

  AGN.N Industry Sector
P/E (TTM): -- 29.89 32.67
EPS (TTM): -11.66 -- --
ROI: -3.08 14.89 14.48
ROE: -5.61 16.01 15.78

UPDATE 2-Drugmakers Endo, Allergan agree to $15 mln in settlements in major opioid case

Aug 20 Endo International Plc and Allergan Plc have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.

Aug 20 2019

Evolus reports sales of its Botox rival ahead of expectations

Medical aesthetics company Evolus Inc on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's Botox, which has dominated the medical aesthetics market for more than a decade.

Aug 12 2019

UPDATE 1-Evolus reports sales of its Botox rival ahead of expectations

Aug 12 Medical aesthetics company Evolus Inc on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's Botox, which has dominated the medical aesthetics market for more than a decade.

Aug 12 2019

Evolus says launch of its Botox rival ahead of its expectations

Aug 12 Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations.

Aug 12 2019

Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand

Allergan Plc , which is being bought by AbbVie Inc for $63 billion, beat quarterly profit estimates and raised its 2019 revenue forecast on Tuesday, helped by demand for its dry eye drug Restasis and aesthetics product Juvederm.

Aug 06 2019

Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand

Aug 6 Allergan Plc, which is being bought by AbbVie Inc for $63 billion, beat quarterly profit estimates and raised its 2019 revenue forecast on Tuesday, helped by demand for its dry eye drug Restasis and aesthetics product Juvederm.

Aug 06 2019

Allergan settles generic Asacol delay claims for nearly $2.75 million

Allergan PLC has agreed to pay nearly $2.75 million to three union-sponsored health benefit plans to resolve a lawsuit alleging that a drugmaker the company now owns suppressed generic competition for its ulcerative colitis drug Asacol.

Aug 05 2019

UPDATE 4-Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat

July 30 Merck & Co Inc reported better-than-expected second-quarter results on Tuesday and raised its full-year earnings forecast on strong demand for its blockbuster cancer immunotherapy Keytruda and vaccines.

Jul 30 2019

AbbVie spotlights Allergan deal, new drugs as Humira sales wane

AbbVie Inc said on Friday a combination of new drugs in its arsenal and its planned $63 billion deal for Botox-maker Allergan Plc will counter declining sales of its long-time bestseller, Humira.

Jul 26 2019

UPDATE 3-AbbVie spotlights Allergan deal, new drugs as Humira sales wane

July 26 AbbVie Inc said on Friday a combination of new drugs in its arsenal and its planned $63 billion deal for Botox-maker Allergan Plc will counter declining sales of its long-time bestseller, Humira.

Jul 26 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates